TickerTalks
Browse all tickers →
TickerTalks›$DCTH
DCDCTH

Delcath Systems, Inc.

$DCTH·$435M·Medical - Devices·Healthcare
$13.20+2.2%YTD+27.4%1Y+1.2%
Mentions · last 7 days
2026-06-24: 8 posts2026-06-25: 2 posts2026-06-26: 7 posts2026-06-27: 0 posts2026-06-28: 2 posts2026-06-29: 5 posts2026-06-30: 3 posts27
Price updated 36m ago·X counts updated 2d ago
DCDCTH
$DCTHDelcath Systems, Inc.
$13.20+2.25%27 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $DCTH, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeWinding up for a moveAI verdict · as of 2026-07-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Delcath Systems at 80% of the 52-week range — HEPZATO commercial ramp for ocular melanoma liver metastases.

Delcath Systems markets HEPZATO KIT — an FDA-approved system for treating unresectable liver metastases from uveal (ocular) melanoma. The equity is up 27% YTD on the continued commercial ramp of the specialty oncology device.

What the fundamentals show:

  • Growth is real — Q1 revenue grew 26.3% year-over-year with operating margin near-breakeven at -1.8%; the trailing PE of 763x reflects the near-breakeven earnings, but PS of 4.8x is defensible.
  • Position and setup — at 80% of the 52-week range +22% above the 200-day, the tape has been running on the launch cadence; the May 13 annual meeting had 67.4% quorum and approved routine amendments.
  • No X sentiment captured — this trades on the specialty-oncology-device commercial thesis rather than crowd narrative.

Stock is up 2.5% today on modest volume — the tape is coiling with the HEPZATO launch trajectory as the primary catalyst. August 5 Q2 earnings is the pivotal test: continued 25%+ revenue growth plus commentary on center-count expansion unlocks the setup, while any launch cadence miss or reimbursement friction breaks the coil. Delcath is a niche play — the ocular-melanoma-liver-mets patient population is real but limited, so the launch curve matters more than the absolute size.

What to watch: August 5 Q2 earnings — HEPZATO revenue growth, center-count expansion, and any commentary on payer coverage. A launch cadence miss extends the coil.

On the calendar: 2026-08-05 — Q2 earnings

no x signal

Read the AI verdict + X sentiment for $DCTH

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Interventional oncology company commercializing HEPZATO KIT for hepatic artery delivery of high-dose melphalan to treat primary and secondary liver cancers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $DCTH.

Medical - Devices · Healthcare

Robotic surgery is the durable secular driver — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures. FDA regulatory acceleration for robotic platforms and emerging non-invasive alternatives (Butterfly Network ultrasound) are secondary structural themes broadening the device innovation landscape.

Industry benchmark

11-name peer basket
-5.2%YTD
+16.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
763.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-0.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-1.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
0.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
86.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.03$-0.09+68.1%
Q4 2025Feb 26, 2026$-0.05$-0.06+20.6%
Q3 2025Nov 4, 2025$0.02$0.020.0%
Q2 2025Aug 6, 2025$0.07$0.03+169.2%
Next earningsWed, Aug 5·consensus EPS $-0.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$25.0M+26.3%85.1%-6.5%$-0.03$287K
Q4 FY25$20.7M+37.3%85.5%-10.5%$-0.05$7.7M
Q3 FY25$20.6M+83.6%87.2%-1.9%$0.02$4.3M
Q2 FY25$24.2M+211.0%86.3%10.7%$0.07$6.9M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$103.2M$100.8M – $104.9M-$0.56-$0.57 – -$0.553
FY27$130.6M$127.6M – $132.7M-$0.53-$0.55 – -$0.523
FY28$156.1M$152.5M – $158.6M-$0.14-$0.45 – $0.175
FY29$181.1M$176.9M – $184.0M$0.35$0.34 – $0.352
FY30$210.9M$206.0M – $214.3M$0.88$0.85 – $0.892

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.80%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+22.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 28.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.525-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMar 6Sandra PennellCFO5.5K sh$50KBuyMar 2Gerard J MichelCEO11.2K sh$100K
+ 11 other (11 awards) in window

See when $DCTH insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeMay 148-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Delcath Systems held its 2026 Annual Meeting on May 13, 2026, with 23,346,271 of 34,618,159 shares (~67.4%) represented. Stockholders approved an amendment to the company's 2020 Omnibus Equity Incentive Plan, adding 1,800,000 shares to the reserve available for equity-based compensation awards. Four proposals were voted upon at the meeting; full vote tallies are included in the filing. The expanded equity plan supports Delcath's ability to attract and retain talent as it commercializes its HEPZATO KIT liver cancer treatment.

SC 13D/AActivist amendmentFeb 10SC 13D/A
8-KPress release / Reg FDJan 128-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD · Item 8.01: Other event
+ 10 other (2 earnings 8-Ks · 2 13Gs · 2 proxys · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstractsbusinesswire.com·37d agoIs Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervaluedgurufocus.com·41d agoDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com·48d agoDelcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conferencebusinesswire.com·52d agoDelcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcriptseekingalpha.com·56d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BIO$TMDX$BFLY$BSX$ISRG$NNOX$ABT$ECOR
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport